Unraveling the next chapter. Sexual development, body image, and sexual functioning in female BRCA carriers

Cancer Journal

Volumn 15, Issue 1, 2009, Pages 15-18

  Matloff, Ellen T ^a,b   Barnett, Rachel E ^a   Bober, Sharon L ^c  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Body image; BRCA1; BRCA2; Fertility; Sexuality

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; TAMOXIFEN;

ARTICLE; BODY IMAGE; BREAST CANCER; CANCER RISK; DISEASE PREDISPOSITION; FERTILITY; GENE MUTATION; GENETIC SCREENING; HIGH RISK POPULATION; HUMAN; HYSTERECTOMY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PREGNANCY; PRIORITY JOURNAL; RISK REDUCTION; SALPINGOOOPHORECTOMY; SEXUAL BEHAVIOR; SEXUAL DEVELOPMENT; SEXUALITY;

EID: 61449116064     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31819585f1     Document Type: Article

References (35)

1. Miki Y, Swenson J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA!. Science. 1994;266:66-71.
2. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789-792.
3. Claus E, Risch N, Thompson W, et al. Autosomal dominant inheritance of early-onset breast cancer. Cancer. 1994;73:643-651.
4. Struewing J, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-1408.
5. Ford D, Easton D, Stratton, M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: the Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676-689.
6. Antoniou A, Pharoah P, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analyses of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
7. King M, Marks J, Mandell J. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643-646.
8. Rebbeck T, Friebel T, Lynch H, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;15:1055-1062.
9. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296:185-192.
10. Eisen A, Lubinski J, Klijn J. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23:7491-7496.
11. Kauff N, Domchek S, Friebel T, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1 and BRCA2 associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26:1331-1337.
12. Domchek S, Friebel T, Neuhausen S, et al. Mortality reduction after risk-reducing bilateral salpingo-oophorectomy in a prospective cohort of BRCA1 and BRCA2 mutation carriers. Lancet Oncol. 2006;7:223-229.
13. Brandberg Y, Sandelin K, Erikson S, et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol. 2008;26:3943-3949.
14. Besser P, Synaeve C, Van Gool A, et al. Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg. 2006;117:1675-1682.
15. Van Oostrom I, Meijers-Heijboer H, Lodder L, et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol. 2003;21:3867-3874.
16. Robson M, Hensley M, Barakat R, et al. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol. 2003;89:281-287.
17. Tercyak K, Peshkin B, Streisand R, et al. Psychosocial issues among children of hereditary breast cancer gene (BRCA1/2) testing participants. Psychooncology. 2001;10:336-346.
18. Biesecker B, Boehnke M, Calzone K, et al. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA. 1993;269:1970-1974.
19. American Society of Clinical Oncology: ASCO policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-2406.
20. American Society of Human Genetics Board of Directors & American College of Medical Genetics Board of Directors: Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet. 1995;57:1233-1241.
21. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian V. 1.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/ genetics_screening.pdf. Accessed September 12, 2008.
22. Matloff E, Moyer A, Shannon K, et al. Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision-making. J Women's Health. 2006;15:843-856.
23. Warner E, Plewes D, Hill K, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;202:1317-1325.
24. Metcalfe K, Lynch H, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328-2335.
25. Gronwald J, Tung N, Foulkes W, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118:2281-2284.
26. Narod S, Brunei J, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet. 2000;356:1876-1881.
27. Stirling D, Evans D, Pichert G, et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of Gynecology and Obstetrics System. J Clin Oncol. 2005;23:5588-5596.
28. McLaughlin J, Risch H, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 2007;8:26-34.
29. McGuire V, Felberg A, Mills M, et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol. 2004;160:613-618.
30. Whittemore A, Balise R, Pharoah P, et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 and BRCA2 mutations. Br J Cancer. 2004;91:1911-1915.
31. Rebbeck T, Lynch H, Neuhausen S, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616-1622.
32. Kauff N, Barakat R. Risk-reducing salpingo-oophorectomy in patients with gertnline mutations in BRCA1 or BRCA2. J Clin Oncol. 2007;25:2921-2927.
33. Matloff E, Caplan A. Direct to confusion: lessons learned from marketing BRCA testing. Am J Bioeth. 2008;8:5-8.
34. Microsort. Available at: www.microsort.net. Vol 2008, 2008.
35. Menon U, Harper J, Sharma A. Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod. 2007;22:1573-1577.